Novel Treatment for Mantle Cell Lymphoma including Therapy-resistant Tumor by NF-κB and mTOR Dual Targeting Approach

Mantle cell lymphoma (MCL) is one of the most aggressive B cell non-Hodgkin lymphomas with a median survival of about five years. Currently, there is no curative therapy available for refractory MCL because of relapse from therapy-resistant tumor cells. The NF-κB and mTOR pathways are constitutively...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Main Authors: Chaturvedi, Nagendra K., Rajule, Rajkumar N., Shukla, Ashima, Radhakrishnan, Prakash, Todd, Gordon L., Natarajan, Amarnath, Vose, Julie M., Joshi, Shantaram S.
Formato: Artigo
Idioma:Inglês
Publicado em: 2013
Assuntos:
Article
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC4124828/
https://ncbi.nlm.nih.gov/pubmed/23963361
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1158/1535-7163.MCT-13-0239
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados